Abstract
The purpose of the study was to map the dominant T cell epitope of the CB11 sequence of CII in RTlu haplotype rats and to determine if, when used as a synthetic peptide, it would induce tolerance to protect against CIA. A dominant epitope corresponding to residues 184-198 included in the sequence of the CB11 fragment of bovine CII was identified in proliferation assay using peptides in an epitope scanning system using synthetic peptides of 15 amino acids, overlapping by 12 amino acids. This epitope is bovine-specific, but cross-reacts with the corresponding rat peptide. Minor epitopes in the bovine CB11 sequence was also autoantigenic. Use of independently synthesized and purified 184-198 peptide confirmed its dominance in the T cell responses of arthritic rats. The peptide itself was not arthritogenic. Cells from lymph nodes draining arthritic feet were particularly responsive to the dominant peptide sequence, and showed evidence of epitope spreading to include reactions to at least four subdominant epitopes. Mucosal tolerance was successfully induced by instilling CII into the nose of rats before induction of CIA: this was found to delay the onset of disease, reduce mean disease severity, shift the anti-CII antibody response to favour antibodies of the IgG1, rather than the IgG2b isiotype, and to reduce T cell reactivity to both CII and to the 184-198 peptide. The dominant 184-198 peptide itself had the same tolerogenic effects when given nasally to rats daily, on the 4 days immediately preceding the induction of CIA. Two forms of CIA with acute and delayed disease onset were each modified by pre-treatment with the peptide. This study demonstrates that mucosal tolerance to CII can be induced by delivering it nasally in a way similar to that achieved previously by oral delivery, and that the use of an immunodominant epitope contained in a synthetic peptide will also suppress the immunologic and arthritic responses to collagen.
MeSH Terms
Administration, Inhalation
Amino Acid Sequence
Animals
Antibody Formation/drug effects
Arthritis, Experimental/immunology,prevention & control
Cattle
Collagen/immunology
Epitope Mapping
Epitopes, T-Lymphocyte/analysis,immunology
Immunity, Mucosal/drug effects,immunology
Immunodominant Epitopes/analysis,immunology
Lymph Nodes/cytology
Lymphocyte Activation
Molecular Sequence Data
Peptide Fragments/immunology,therapeutic use
Rats
Rats, Inbred Strains
Sequence Homology, Amino Acid
T-Lymphocytes/drug effects,immunology
Chemicals
Epitopes, T-Lymphocyte
Immunodominant Epitopes
Peptide Fragments
Collagen
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Staines N A
Infection and Immunity Research Group, Division of Life Sciences, Kings College, London, UK.
Harper N
Ward F J
Malmström V
Holmdahl R
Bansal S
References (29)
29 references, click to expand
-
Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats.
Clin Exp Immunol. 1986 Jun;64(3):581-6
PMID: 3791692
-
Tolerogenic activity of polymerized type II collagen in preventing collagen-induced arthritis in rats.
Clin Exp Immunol. 1988 Apr;72(1):20-5
PMID: 3396219
-
Effects of oral administration of type II collagen on rheumatoid arthritis.
Science. 1993 Sep 24;261(5129):1727-30
PMID: 8378772
-
Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection.
Eur J Immunol. 1992 Jul;22(7):1819-25
PMID: 1378019
-
Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.
Eur J Immunol. 1993 Mar;23(3):591-9
PMID: 7680609
-
Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis.
J Exp Med. 1989 Dec 1;170(6):1999-2010
PMID: 2479704
-
Identification and characterization of a tolerogenic T cell determinant within residues 181-209 of chick type II collagen.
Clin Immunol Immunopathol. 1995 Apr;75(1):33-8
PMID: 7533683
-
Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.
Int Immunol. 1993 Sep;5(9):1159-65
PMID: 7694644
-
Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity.
J Immunol. 1988 Mar 1;140(5):1477-84
PMID: 3257978
-
Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.
Int J Pept Protein Res. 1990 Mar;35(3):161-214
PMID: 2191922
-
Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis.
Immunology. 1988 Oct;65(2):305-10
PMID: 3192274
-
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens.
Annu Rev Immunol. 1994;12:809-37
PMID: 8011298
-
Covalent structure of collagen. Amino acid sequence of an arthritogenic cyanogen bromide peptide from type II collagen of bovine cartilage.
Eur J Biochem. 1989 Apr 15;181(1):159-73
PMID: 2714276
-
Suppression of collagen-induced arthritis with pergastrically or intravenously administered type II collagen.
Agents Actions. 1986 Dec;19(5-6):318-9
PMID: 3825748
-
Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen.
J Immunol. 1990 Oct 15;145(8):2489-93
PMID: 2120332
-
Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens.
Br J Ophthalmol. 1993 Mar;77(3):171-5
PMID: 8457510
-
The role of nasopharyngeal lymphoid tissue.
Immunol Today. 1992 Jun;13(6):219-24
PMID: 1627250
-
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421-5
PMID: 1370356
-
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.
J Immunol. 1988 Jan 15;140(2):440-5
PMID: 2447178
-
Rapid method to determine structural polymorphism of rat major histocompatibility complex class II genes.
Transplant Proc. 1993 Oct;25(5):2770
PMID: 8212230
-
Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen.
J Immunol. 1990 Mar 1;144(5):1689-95
PMID: 2137841
-
Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression.
Autoimmunity. 1993;16(3):189-99
PMID: 8003614
-
Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.
Cell Immunol. 1988 Apr 1;112(2):364-70
PMID: 2451570
-
The covalent structure of cartilage collagen. Evidence for sequence heterogeneity of bovine alpha1(II) chains.
J Biol Chem. 1977 Jan 25;252(2):639-43
PMID: 833147
-
Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.
Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6
PMID: 3463976
-
Prevention of pristane-induced arthritis by the oral administration of type II collagen.
Immunology. 1993 May;79(1):152-7
PMID: 8509136
-
Arthritis: animal models of oral tolerance.
Ann N Y Acad Sci. 1996 Feb 13;778:297-305
PMID: 8610983
-
Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen.
Arthritis Rheum. 1995 Aug;38(8):1092-6
PMID: 7639805
-
Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial.
Arthritis Rheum. 1996 Jan;39(1):41-51
PMID: 8546737